Inrebic: animal efficacy model or human cells?

“In vivo studies in mouse models of JAK2V617F-driven myeloproliferative disease showed that twice daily oral doses of fedratinib at 60 or 120 mg/kg blocked phosphorylation of STAT3/5, increased survival to 100% at the highest dose after 42 days of treatment, and improved disease-associated symptoms, including reduction of white blood cells, hematocrit, splenomegaly, and fibrosis.”

“Numerous in vivo mouse models were used to evaluate the efficacy of fedratinib. Although proof of concept is shown in these studies, it appears that in mice a higher exposure to fedratinib than the exposure reached in humans is required to result in an effect on tumour cells.”